HLA-A*24:02-restricted M-phase phosphoprotein 1 (278-286) peptide-MHC complex (HLA-A24/MPHOSPH1-278)

The HLA-A24 presenting MPHOSPH1 278-286 epitope is a peptide-major histocompatibility complex (pMHC) consisting of a 9-amino acid fragment (IYNEYIYDL) derived from the M-phase phosphoprotein 1 (MPHOSPH1, also known as KIF20B) presented by the HLA-A*24:02 molecule (PubMed: 15150592). MPHOSPH1 is a kinesin-related motor protein essential for the completion of cytokinesis during the cell cycle (UniProt: Q96Q89). While its expression is minimal in most normal adult tissues, it is significantly upregulated in various malignancies, including bladder, lung, and esophageal carcinomas, making it a viable tumor-associated antigen (TAA). This specific epitope is highly immunogenic and serves as a target for cancer immunotherapy, particularly in East Asian populations where the HLA-A24 allele is prevalent (PubMed: 17459057). Therapeutic strategies targeting this complex include peptide-based vaccines, such as OTS102, and T-cell receptor (TCR) engineered T-cell therapies designed to trigger a cytotoxic T lymphocyte (CTL) response against tumor cells. Clinical trials have demonstrated that targeting this epitope can elicit specific immune responses and potentially improve survival in patients with advanced cancers.

Other names

MPHOSPH1-278KIF20B-278IYNEYIYDL peptideM-phase phosphoprotein 1 (278-286)HLA-A24-MPHOSPH1 epitope

Induction of peptide-specific cytotoxic T lymphocytes (CTLs) that recognize and lyse tumor cells presenting the MPHOSPH1-derived peptide in the context of HLA-A*24:02.